Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
FDA rejects J&J’s subcutaneous Rybrevant over manufacturing issues
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
December 18, 2024